Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 4/20 | 0.39 |
| ▸ | MET | P08581 | 2/20 | 0.39 |
| ▸ | SCN4A | P35499 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1964982 | 0.81 | HSPB1 (0.48) | HSPB1MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL12405902 | 0.81 | ALDH1A1 (0.41) | HSPB1KDM4EMEN1KMT2AHTT | |
| SCHEMBL16863281 | 0.76 | HSPB1 (0.42) | ATMHSPB1KDM4EMEN1KMT2A | |
| SCHEMBL3484559 | 0.76 | KMT2A (0.56) | HSPB1KDM4EMEN1KMT2AHTT | |
| SCHEMBL16863242 | 0.72 | AXL (0.45) | MEN1KMT2AALDH1A1AXLMET | |
| SCHEMBL7632959 | 0.71 | HSPB1 (0.66) | HSPB1KDM4EMEN1KMT2AHTT | |
| SCHEMBL30545049 | 0.71 | HSPB1 (0.45) | ATMHSPB1MEN1KMT2AHTT | |
| SCHEMBL18186591 | 0.70 | AXL (0.52) | ATMAXLMET | |
| SCHEMBL16863307 | 0.69 | PARP10 (0.51) | KMT2AALDH1A1AXLMET | |
| SCHEMBL11689190 | 0.69 | HSPB1 (0.79) | HSPB1KDM4EMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165445-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165445-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC. (US) | 2013-06-27 | — | — | US | disclosed |
| EP-2288611-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2013-05-15 | — | — | EP | disclosed |
| US-8404694-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404694-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20110065709-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110065709-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2011-03-17 | — | — | US | disclosed |
| EP-2288611-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | Amgen Inc. (US) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009117157-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065709-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, AURKB | ATM 225/4885HSPB1 3524/4885KDM4E 882/4885 |
| US-20130165445-A1 | Aurora Kinase Modulators and Method of Use | AURKC, AURKA, AURKB | ATM 225/4885HSPB1 3524/4885KDM4E 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.